Investor Overview

Organovo has been a pioneer in the development of 3-D bioprinted tissues comprised of human cells. After Organovo concluded that it had not generated decisive scientific data supporting the prolonged functionality and therapeutic benefit of its lead therapeutic liver tissue candidate, Organovo implemented a restructuring plan to significantly reduce expenses in order to focus on evaluating strategic alternatives, while retaining certain key management, IP, licenses, collaborations, and proprietary equipment.

2018 Annual Report
Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

© 2020 Organovo Holdings, Inc. 6275 Nancy Ridge Drive, Suite 110 San Diego, CA 92121